Trial Profile

A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atropine (Primary)
Indications Myopia
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms STAR
Sponsors Sydnexis

Most Recent Events

04 Nov 2025 According to a Sydnexis media release, results from this study were presented in a poster session at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 in National Harbor, MD.
04 Nov 2025 Primary endpoint (Myopic progression 0.75 D (diopters)) has been met, according to a Sydnexis media release.
04 Nov 2025 Results from this trial presented in the Sydnexis Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com